Article: Dey Launches and Unveils Next-Generation, Needle-Protected EpiPen[R] (Epinephrine) Auto-Injector with Enhanced Patient-Friendly Features.

Dey Pharma, L.P., a subsidiary of Mylan Inc. (NASDAQ:MYL), today launched a newly designed, patient-friendly EpiPen=AE Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use (see also Anaphylactic Shock).

Dey President Carolyn Myers, Ph.D., said: "We are very pleased to be launching Dey's highly anticipated next-generation, needle-protected EpiPen Auto-Injector. The objective of the product's new features is to give those who carry an epinephrine ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!